FDA Approves Pembrolizumab Alongside Standard Chemotherapy As First-Line Therapy For Certain Patients With Cervical Cancer

Medscape (10/13, Stern, Subscription Publication) reported, “The US Food and Drug Administration (FDA) has approved the checkpoint inhibitor pembrolizumab…alongside standard chemotherapy — with or without bevacizumab — as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.” The agency “also announced the regular approval of pembrolizumab alone for patients with recurrent or metastatic cervical cancer experiencing disease progression during or post-chemotherapy.”